PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer. (Q53398122)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234767%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234767%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234767%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Paula González-Alonso

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234767%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Ion Cristóbal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234767%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Rebeca Manso

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234767%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Juan Madoz-Gúrpide

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234767%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Jesús García-Foncillas

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234767%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

4 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234767%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234767%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234767%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234767%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

5753-5755

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234767%20AND%20SRC:MED&resulttype=core&format=json

Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3849-5

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3849-5

alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3849-5

Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3849-5

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3849-5

CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3849-5

CIP2A mediates prostate cancer progression via the c-MYC signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3849-5

Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3849-5

Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3849-5

Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3849-5

Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3849-5

PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3849-5

Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3849-5

Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3849-5

10.1007/S13277-015-3849-5

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234767%20AND%20SRC:MED&resulttype=core&format=json

release_pf2p3y6swjfezeducqephftjn4

20 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pf2p3y6swjfezeducqephftjn4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference